EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Xtandi (enzalutamide) for prostate cancer, with Astellas Pharma Europe B.V. as the MAH (decision date 12/02/2026).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 12/02/2026